Dr Richard Goldberg discusses how outdated FDA metrics may delay immunotherapy approvals for oncology agents. Immunotherapy ...
ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
New in the NCCN guidelines is lurbinectedin [Zepzelca] and atezolizumab [Tecentriq] maintenance. 2 There are other ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides ...
Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
Dr Singh also takes viewers inside the critical—and often underappreciated—role of multidisciplinary collaboration, ...
Early-line data appears encouraging, with MajesTEC-3 complemented by emerging newly diagnosed data showing near-universal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results